Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms

被引:16
作者
Beinborn, M [1 ]
Ren, Y [1 ]
Bläker, M [1 ]
Chen, C [1 ]
Kopin, AS [1 ]
机构
[1] Tufts Univ, New England Med Ctr, Mol Pharmacol Res Ctr, Dept Med, Boston, MA 02111 USA
关键词
D O I
10.1124/mol.65.3.753
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been proposed that mutations that induce constitutive activity in G-protein-coupled receptors (GPCRs) concomitantly enhance the ability of partial agonists to trigger second-messenger signaling. Using the cholecystokinin type 2 receptor (CCK-2R) as a model system, we have explored whether this association applies to a diverse set of activating mutations. Consistent with established principles, constitutively active CCK-2Rs resulting from amino acid substitutions within the third intracellular loop each systematically increased partial agonist activities versus corresponding wild-type values. In contrast, activating mutations within transmembrane domain segments near the extracellular loops led to an increase in efficacy of only a subset of compounds but decreased or did not change the function of others. When transmembrane domain amino acid substitutions were introduced in combination with intracellular amplifying mutations, observed changes in ligand activity were defined by the product of two discernible factors 1) systematic amplification caused by an equilibrium shift from the inactive to the active receptor conformation and 2) ligand-specific alterations in signaling, which probably result from mutation-induced changes in the putative binding pocket. These findings illustrate functional heterogeneity among GPCR mutants with ligand-independent signaling. A subgroup of activating mutations facilitates receptor isomerization to the active state and in parallel perturbs ligand receptor interactions. These mutants do not adhere to the previously proposed "hallmark criteria" of constitutive activity.
引用
收藏
页码:753 / 760
页数:8
相关论文
共 40 条
[1]  
BALLESTEROS JA, 1995, RECEPTOR MOL BIOL, P366
[2]   Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties [J].
Beinborn, M ;
Quinn, SM ;
Kopin, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14146-14151
[3]   A SINGLE AMINO-ACID OF THE CHOLECYSTOKININ-B GASTRIN RECEPTOR DETERMINES SPECIFICITY FOR NONPEPTIDE ANTAGONISTS [J].
BEINBORN, M ;
LEE, YM ;
MCBRIDE, EW ;
QUINN, SM ;
KOPIN, AS .
NATURE, 1993, 362 (6418) :348-350
[4]  
Beinborn M, 1998, YALE J BIOL MED, V71, P337
[5]   CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides [J].
Bläker, M ;
Ren, Y ;
Seshadri, L ;
McBride, EW ;
Beinborn, M ;
Kopin, AS .
MOLECULAR PHARMACOLOGY, 2000, 58 (02) :399-406
[6]   Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists [J].
Bläker, M ;
Ren, Y ;
Gordon, MC ;
Hsu, JE ;
Beinborn, M ;
Kopin, AS .
MOLECULAR PHARMACOLOGY, 1998, 54 (05) :857-863
[7]   MOLECULAR CHARACTERIZATION OF A COMMON BINDING-SITE FOR SMALL MOLECULES WITHIN THE TRANSMEMBRANE DOMAIN OF G-PROTEIN COUPLED RECEPTORS [J].
CASCIERI, MA ;
FONG, TM ;
STRADER, CD .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1995, 33 (04) :179-185
[8]  
Chen G, 2000, MOL PHARMACOL, V57, P125
[9]   Therapeutic and chemical developments of cholecystokinin receptor ligands [J].
de Tullio, P ;
Delarge, J ;
Pirotte, B .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) :129-146
[10]   Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the β2-adrenergic receptor [J].
Del Carmine, R ;
Ambrosio, C ;
Sbraccia, M ;
Cotecchia, S ;
Ijzerman, AP ;
Costa, T .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (07) :1715-1722